Article

Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models

School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, UK.
British Journal of Clinical Pharmacology (Impact Factor: 3.69). 01/2011; 71(1):72-87. DOI: 10.1111/j.1365-2125.2010.03799.x
Source: PubMed

ABSTRACT The prediction of drug-drug interactions (DDIs) from in vitro data usually utilizes an average dosing interval estimate of inhibitor concentration in an equation-based static model. Simcyp®, a population-based ADME simulator, is becoming widely used for the prediction of DDIs and has the ability to incorporate the time-course of inhibitor concentration and hence generate a temporal profile of the inhibition process within a dynamic model.
Prediction of DDIs for 35 clinical studies incorporating a representative range of drug-drug interactions, with multiple studies across different inhibitors and victim drugs. Assessment of whether the inclusion of the time course of inhibition in the dynamic model improves prediction in comparison with the static model. Investigation of the impact of different inhibitor and victim drug parameters on DDI prediction accuracy including dosing time and the inclusion of active metabolites. Assessment of ability of the dynamic model to predict inter-individual variability in the DDI magnitude.
Static and dynamic models (incorporating the time course of the inhibitor) were assessed for their ability to predict drug-drug interactions (DDIs) using a population-based ADME simulator (Simcyp®V8). The impact of active metabolites, dosing time and the ability to predict inter-individual variability in DDI magnitude were investigated using the dynamic model.
Thirty-five in vivo DDIs involving azole inhibitors and benzodiazepines were predicted using the static and dynamic model; both models were employed within Simcyp for consistency in parameters. Simulations comprised of 10 trials with matching population demographics and dosage regimen to the in vivo studies. Predictive utility of the static and dynamic model was assessed relative to the inhibitor or victim drug investigated.
Use of the dynamic and static models resulted in comparable prediction success, with 71 and 77% of DDIs predicted within two-fold, respectively. Over 40% of strong DDIs (>five-fold AUC increase) were under-predicted by both models. Incorporation of the itraconazole metabolite into the dynamic model resulted in increased prediction accuracy of strong DDIs (80% within two-fold). Bias and imprecision in prediction of triazolam DDIs were higher in comparison with midazolam and alprazolam; >50% of triazolam DDIs were under-predicted regardless of the model used. Predicted inter-individual variability in the AUC ratio (coefficient of variation of 45%) was consistent with the observed variability (50%).
High prediction accuracy was observed using both the Simcyp dynamic and static models. The differences observed with the dose staggering and the incorporation of active metabolite highlight the importance of these variables in DDI prediction.

Download full-text

Full-text

Available from: Geoffrey T Tucker, Jun 23, 2015
0 Followers
 · 
104 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Here, we summarize the discussion topics at the 2013 AAPS symposium on “Dealing with complex drug-drug interactions: towards mechanistic models”. The unmanageable adverse events caused by drug-drug interactions (DDIs), leading to market withdrawal or restriction in use, are increasingly being avoided with our improvement in quantitative prediction of DDIs early in drug development, and that significant challenges remain when inhibitor drugs and/or metabolites affect not one but multiple pathways of clearance. Physiologically based pharmacokinetic (PBPK) models, in combination with established in vitro-to-in vivo extrapolations of intestinal and hepatic disposition, have been successfully applied to predict clinical pharmacokinetics and DDIs, especially for drugs with CYP-mediated metabolism, and to explain transporter-mediated and complex DDIs. Although continuous developments are being made towards improved mechanistic prediction of the transporter-enzyme interplay in the hepatic and intestinal disposition and characterizing the metabolites contribution to DDIs, prediction of both enzyme and transporter mediated DDI remains difficult. Regulatory guidelines recommended use of PBPK modeling for the quantitative prediction and evaluation of DDIs involving multiple perpetrators and metabolites. Such mechanistic modeling approaches culminate to the consensus that modeling is helpful in predicting DDIs and quantitatively rationalize clinical findings in complex situations. Furthermore, they provide the basis for the prediction and/or understanding pharmacokinetics in different populations: renally impaired, pediatrics, or ethnic groups where the conduct of clinical studies might not be feasible in early drug development stages, but some guidance on management of dosage is necessary. This article is protected by copyright. All rights reserved.
    Biopharmaceutics & Drug Disposition 12/2014; 36(2). DOI:10.1002/bdd.1934 · 2.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A distinguishing feature of physiologically based pharmacokinetic (PBPK) models is that modeling starts from a mathematical structure representing the physiology of interest. The model is highly parameterized with parameter values based on measured anatomical/ physiological data. PBPK models are implemented as a series of linked differential equations that are solved numerically on the computer to track the time course of drug concentrations in blood and tissues. PBPK models can be useful guides in the research and development of new drugs from the early discovery phase through to clinical development. By linking to pharmacodynamic models incorporating pharmacology data, PK/pharmacodynamics (PD) relationships can be modeled facilitating a quantitative, science-driven decision. PBPK models are increasingly replacing more empirical approaches in pharmaceutical research. Their strength is the ability to incorporate, in a mechanistic framework, the various data generated during drug discovery and development.
    Predictive ADMET, Edited by Jianling Wang, Laszlo Urban, 03/2014: chapter PBPK: Integrating In Vitro and In Silico Data in Physiologically Based Models: pages 167-188.; John Wiley & Sons, Inc..
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatobiliary transport mechanisms have been identified to play a significant role in determining the systemic clearance for a number of widely prescribed drugs and an increasing number of new molecular entities (NMEs). While determining the pharmacokinetics, drug transporters also regulate the target tissue exposure and play a key role in regulating the pharmacological and/or toxicological responses. Consequently, it is of great relevance in drug discovery and development to assess hepatic transporter activity in regard to pharmacokinetic and dose predictions and to evaluate pharmacokinetic variability associated with drug-drug interactions (DDIs) and genetic variants. Mechanistic predictions utilizing physiological-based pharmacokinetic modeling are increasingly used to evaluate transporter contribution and delineate the transporter-enzyme interplay on the basis of hypothesis-driven functional in vitro findings. Significant strides were made in the development of in vitro techniques to facilitate characterization of hepatobiliary transport. However, challenges exist in the quantitative in vitro-in vivo extrapolation of transporter kinetics due to the lack of information on absolute abundance of the transporter in both in vitro and in vivo situations, and/or differential function in the holistic in vitro reagents such as suspended and plated hepatocytes systems, and lack of complete mechanistic understanding of liver model structure. On the other hand, models to predict transporter-mediated DDIs range from basic models to mechanistic static and dynamic models. While basic models provide conservative estimates and are useful upfront in avoiding false negative predictions, mechanistic models integrate multiple victim and perpetrator drugs parameters and are expected to provide quantitative predictions. The aim of this paper is to review the current state of the model-based approaches to predict clinical pharmacokinetics and DDIs of drugs or NMEs that are substrates of hepatic transporters.
    Clinical Pharmacokinetics 07/2014; 53(8). DOI:10.1007/s40262-014-0156-z · 5.49 Impact Factor